[ad_1] Based on FDA comments, Voyager Therapeutics (NASDAQ: VYGR) says it is maintaining its plan to submit a BLA seeking approval for VY-AADC gene therapy based on live data 2. He says …
Read More »Traveling Advance Gene Therapy for Parkinson's Disease, Phase 2 Data May Be Sufficient for Marketing Application in the United States – Voyager Therapeutics (NASDAQ: VYGR)
